Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Apr 15;26(8):756-84.
doi: 10.1101/gad.187922.112.

Emerging insights into the molecular and cellular basis of glioblastoma

Gavin P Dunn  1 , Mikael L Rinne, Jill Wykosky, Giannicola Genovese, Steven N Quayle, Ian F Dunn, Pankaj K Agarwalla, Milan G Chheda, Benito Campos, Alan Wang, Cameron Brennan, Keith L Ligon, Frank Furnari, Webster K Cavenee, Ronald A Depinho, Lynda Chin, William C Hahn
Affiliations
Review

Emerging insights into the molecular and cellular basis of glioblastoma

Gavin P Dunn et al. Genes Dev. .

Abstract

Glioblastoma is both the most common and lethal primary malignant brain tumor. Extensive multiplatform genomic characterization has provided a higher-resolution picture of the molecular alterations underlying this disease. These studies provide the emerging view that "glioblastoma" represents several histologically similar yet molecularly heterogeneous diseases, which influences taxonomic classification systems, prognosis, and therapeutic decisions.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Genomic alterations underlying gliomagenesis. Both primary and secondary glioblastomas arise from precursor cells that may be distinct. Primary glioblastomas arise de novo and exhibit p53 and Rb pathway dysfunction as well as RTK/Ras/PI3K signaling dysregulation, leading to tumors that arise in older patients with a worse prognosis, likely owing to the predominant wild-type IDH1 genotype. In contrast, secondary glioblastomas are preceded by lower-grade II lesions, which progress either through grade III lesions or directly to glioblastoma. These tumors occur in younger patients and are dominated by a mutant IDH1 genotype that confers a better prognosis and is associated with a more restricted frontal lobe location.
Figure 2.
Figure 2.
Molecular heterogeneity in glioblastoma. (A) Immunohistochemistry for the mutant EGFR receptor EGFRvIII demonstrates a heterogeneous staining pattern within the tumor. Images from Nishikawa et al. (2004) used with permission. (B) Multicolor FISH reveals distinct subpopulations of either EGFR (red) or PDGFRA (green) amplification within a glioblastoma specimen. Images obtained from Cameron Brennan.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, et al. 2012. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest 122: 253–266 - PMC - PubMed
    1. Akhavan D, Cloughesy TF, Mischel PS 2010. mTOR signaling in glioblastoma: Lessons learned from bench to bedside. Neuro Oncol 12: 882–889 - PMC - PubMed
    1. Akiyama Y, Jung S, Salhia B, Lee S, Hubbard S, Taylor M, Mainprize T, Akaishi K, van Furth W, Rutka JT 2001. Hyaluronate receptors mediating glioma cell migration and proliferation. J Neurooncol 53: 115–127 - PubMed
    1. Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK, Alvarez-Buylla A, Parada LF 2009. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15: 45–56 - PMC - PubMed
    1. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T, et al. 2011a. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 224: 334–343 - PubMed

Publication types